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Triple-negative breast cancers have a propensity to metastasize and a poor outcome relative 
to other breast cancer subtypes. No molecularly targeted therapies exist for triple-negative 
disease and the standard of care for remains surgery followed by adjuvant radiotherapy 
and/or chemotherapy. Therefore, new therapies that target the molecular alterations present in 
triple-negative tumors are needed to either prevent metastatic dissemination or kill 
micrometastatic lesions at distant sites. The serglycin gene encodes a large secreted 
proteoglycan decorated with chondroitin sulfate modifications and expressed primarily by the 
hematopoietic system.1 While serglycin was recently shown to be expressed by mammary 
epithelial cells2, its role in breast oncogenesis is unclear.  
Methods  
Serglycin expression was analyzed by RNA-based (qRT-PCR) and protein-based 
(immunohistochemistry) methods3. Serglycin expression was specifically knocked down in 
triple-negative breast cancer lines (MDA-MB-231_HM4, SUM159) by shRNA technology 
using the pGIPZ lentiviral system. Genetically engineered cells were assessed in vitro using 
standard assays. Tumor growth and spontaneous metastasis to lung, liver and spleen was 
analyzed in vivo by orthotopic inoculation of cells into Nod.Scid.IL-2Rgamma-null (NSG)5 
immuno-deficient mice.  
Results 
Serglycin was found to over-expressed in a subset of triple-negative breast cancers as well as 
in several metastatic triple-negative/claudin-low breast cancer cell lines including MDA-MB-
231, SUM159 and Hs578T. Knockdown of serglycin was engineered in highly-metastatic 
MDA-MB-231_HM (231_HM) cells and in a metastatic variant of SUM159 cells. In vivo 
experiments showed that knockdown of serglycin reduced the growth rate of primary 
231_HM tumours implanted in the mammary fat pads of mice. Moreover, following resection 
of the primary tumours, spontaneous metastasis to lung, liver and spleen was reduced in 





The hematopoietic proteoglycan serglycin is over-expressed in a subset of triple-negative 
breast cancers and may represent a novel target for anti-cancer therapy.  
References: 
1. Korpetinou A, et al., Serglycin: at the crossroad of inflammation and malignancy. Front 
Oncol. 2014 3:327 
2. Korpetinou A, et al., Serglycin is implicated in the promotion of aggressive phenotype of 
breast cancer cells. PLoS One 2013 8:e78157  
3. Li XJ, et al., Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes 
metastasis. Cancer Res. 2011 71:3162-3172  
4. Chang XZ, et al., Identification of the functional role of peroxiredoxin 6 in the progression 
of breast cancer. Breast Cancer Res. 2007 9:R76  
5. Shultz LD, et al., Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R 
gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005 
174:6477-6489  
 
